Contributions
Abstract: P1128
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Objective: Oxidative injury has been implicated in tissue damage in multiple sclerosis (MS). High levels of nitric oxide (NO) play an important role in cytotoxicity. NO although not toxic itself, it reacts with superoxide to form peroxynitrite. Peroxynitrite cannot be detected directly but it nitrates tyrosine residues to form nitrotyrosine (NT), which is considered its foot-print. The activated microglia is responsible for the release of NO through activation of nitric oxide synthetase (NOS) in the form of endothelial NOS, neuronal NOS (nNOS), inducible NOS (iNOS) and mitochondrial NOS. The aim of our study was to compare the levels of NT, nNOS and iNOS in patients with clinically isolated syndrome (CIS) relapsing remitting (RRMS) and progressive (PMS) MS and to examine the correlation of their levels with demographic and clinical variables.
Methods: In this study, 33 CIS, 40 RRMS, 32 PMS patients and 18 aged matched control subjects were included. Clinical data collected were age, disease duration, medication and Expanded Disability Status Scale score. NT, nNOS and iNOS levels were measured in serum and CSF using the enzyme-linked immunosorbent assay (ELISA). A non-parametric Kruskal-Wallis test was used for multiple comparisons (significant p value < 0.05). For comparisons of patients with controls the non-parametric Mann-Whitney U test with Bonferroni correction was used.
Results: Mean age of the patients was 36,05 ± 8,79 years, disease duration 53,96 months and EDSS score ≤4. NT serum levels were elevated in CIS and PMS patients, compared to controls (p=0,004 and p=0,0001 respectively), as were in PMS compared to RRMS (p=0,002) patients. iNOS serum levels were also increased in CIS (p=0,006) and PMS (p=0,002) patients regarding controls. iNOS CSF levels were high in PMS compared to controls (p=0,002), CIS (p=0,0001) and RRMS (p = 0,001) patients. NT serum/CSF value was smaller for controls than PMS patients (p=0,006). Finally, iNOS serum/CSF was consistently less in PMS patients than controls (p=0,001), CIS (p=0,001) and RRMS patients (p=0,003).
Conclusion: CIS and RRMS patients did not differ regarding the studied parameters, whereas NT levels were higher in PMS, suggesting that NT may be used as a marker of disease progression. This implies that measurement of NO-related metabolites may help in the detection of possible disease activity and even the prediction of therapeutic response, offering optimum clinical monitoring for the patient.
Disclosure: Nothing to disclose
Abstract: P1128
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Objective: Oxidative injury has been implicated in tissue damage in multiple sclerosis (MS). High levels of nitric oxide (NO) play an important role in cytotoxicity. NO although not toxic itself, it reacts with superoxide to form peroxynitrite. Peroxynitrite cannot be detected directly but it nitrates tyrosine residues to form nitrotyrosine (NT), which is considered its foot-print. The activated microglia is responsible for the release of NO through activation of nitric oxide synthetase (NOS) in the form of endothelial NOS, neuronal NOS (nNOS), inducible NOS (iNOS) and mitochondrial NOS. The aim of our study was to compare the levels of NT, nNOS and iNOS in patients with clinically isolated syndrome (CIS) relapsing remitting (RRMS) and progressive (PMS) MS and to examine the correlation of their levels with demographic and clinical variables.
Methods: In this study, 33 CIS, 40 RRMS, 32 PMS patients and 18 aged matched control subjects were included. Clinical data collected were age, disease duration, medication and Expanded Disability Status Scale score. NT, nNOS and iNOS levels were measured in serum and CSF using the enzyme-linked immunosorbent assay (ELISA). A non-parametric Kruskal-Wallis test was used for multiple comparisons (significant p value < 0.05). For comparisons of patients with controls the non-parametric Mann-Whitney U test with Bonferroni correction was used.
Results: Mean age of the patients was 36,05 ± 8,79 years, disease duration 53,96 months and EDSS score ≤4. NT serum levels were elevated in CIS and PMS patients, compared to controls (p=0,004 and p=0,0001 respectively), as were in PMS compared to RRMS (p=0,002) patients. iNOS serum levels were also increased in CIS (p=0,006) and PMS (p=0,002) patients regarding controls. iNOS CSF levels were high in PMS compared to controls (p=0,002), CIS (p=0,0001) and RRMS (p = 0,001) patients. NT serum/CSF value was smaller for controls than PMS patients (p=0,006). Finally, iNOS serum/CSF was consistently less in PMS patients than controls (p=0,001), CIS (p=0,001) and RRMS patients (p=0,003).
Conclusion: CIS and RRMS patients did not differ regarding the studied parameters, whereas NT levels were higher in PMS, suggesting that NT may be used as a marker of disease progression. This implies that measurement of NO-related metabolites may help in the detection of possible disease activity and even the prediction of therapeutic response, offering optimum clinical monitoring for the patient.
Disclosure: Nothing to disclose